CClinicalTrials.gg
Status unknownNCT03956485HIC-CATUpdated May 20, 2019

Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).

An observational study in Intracerebral Hemorrhage, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Status unknown at 26 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-20.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

A population-based registry in Catalonia of patients with acute spontaneous Intracerebral Hemorrhage, to investigate whether type of center and time from onset to admission is associated with functional outcome and mortality.

Read the detailed description

Introduction. Recent studies show that there are potentially beneficial therapeutic measures for the patient with acute intracerebral hemorrhage (ICH), which should be applied urgently and that some would only be available in tertiary stroke centers (TSC). However, the transportation criteria for ICH patients are not well defined.

Objectives: Design and implementation of a registry (HIC-CAT) of patients with HIC in the healthcare network of public hospitals in Catalonia, which does not modify the current logistics but collects data related to patients and TSC, interhospital transfers and non-TSC centers. The registry will allow us to evaluate the hypothesis that: 1) Patient care in TSC decreases the probability of death or dependence in patients with spontaneous ICH compared to non-TSC; and 2) The shorter the time until admission to a TSC, the better the survival and functional outcome. This will be due to the application of diagnostic, therapeutic and structural measures at the TSC. In addition, organ donation will be more frequent in a TSC.

Methods: Observational, prospective, multicentre, population study of 2500 consecutive patients with spontaneous ICH of less than 24 hours from the onset of symptoms and Rankin scale score 0-3. We will collect times, clinical and radiological variables, vital and functional outcome at 3 months follow-up. Number of organ donations. Primary variable: Functional outcome at 3 months (Rankin 0-3). Statistics: Multivariate analysis with logistic regression, propensity matching scores.

02

Conditions studied

  • Intracerebral Hemorrhage

Keywords

  • intracerebral hemorrhage
  • outcome
  • transportation
  • transfer
  • prognosis
03

In context

Cerebral Hemorrhage

476 studies on the registry are indexed under Cerebral Hemorrhage; 181 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 275 across 180 observational studies indexed under Cerebral Hemorrhage.

Browse Cerebral Hemorrhage studies →

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 335 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with a diagnosis of acute spontaneous intracerebral hemorrhage in Catalonia during a period of 2 years

Inclusion criteria

  • Patient with a diagnosis of spontaneous intracerebral hemorrhage who is diagnosed in any of the participant hospitals

Exclusion criteria

Exclusion Criteria:

  • Traumatic intracerebral hemorrhage
  • >24 hours from onset to admission
  • Prior Rankin scale score >3
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • OtherType of center

    Tertiary versus non-tertiary

    Also known as: Time from onset to admission

06

What researchers measure

Primary outcomes

  1. Functional outcome

    Rankin scale score, favourable if 0,1, 2 or 3

    Time frame: 3 months after onset

Secondary outcomes

  1. Mortality

    mortality within the first 3 months after onset

    Time frame: 3 months

  2. Hematoma expansion

    increase in hematoma volume (\>33% and/or 6 ml) from baseline CT to follow-up CT

    Time frame: 72 hours

  3. Stroke Unit admission

    Percentage of patients admitted to a stroke unit

    Time frame: 3 months

  4. Neurological worsening

    increase in 4 or more points in the NIHSS score and/or decrease \>1 point in the Glasgow coma scale score

    Time frame: During admission

07

Study locations

26 sites
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona, Spain
  • Fundació Hospital Asil Granollers
    Granollers, Barcelona, Spain
  • Hospital d'Igualada
    Igualada, Barcelona, Spain
  • Hospital de Bellvitge
    L'Hospitalet De Llobregat, Barcelona, Spain
  • Hospital de Mataró
    Mataró, Barcelona, Spain
  • Hospital Parc Taulí
    Sabadell, Barcelona, Spain
  • Hospital Moisés Broggi
    Sant Joan Despí, Barcelona, Spain
  • Mutua de Terrassa
    Terrassa, Barcelona, Spain
  • Hospital de Figueras
    Figueras, Girona, Spain
  • Hospital de Palamós
    Palamós, Girona, Spain
  • Fundació Sant hospital de la Seu d'Urgell
    La Seu d'Urgell, Lleida, Spain
  • Hospital de Tremp
    Tremp, Lleida, Spain
  • Hospital de la Cinta
    Tortosa, Tarragona, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Consorci Sanitari del Garraf
    Barcelona, Spain
  • Hospital Clínic
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Dr Josep Trueta
    Girona, Spain
  • Hospital Arnau de Vilanova
    Lleida, Spain
  • Hospital de la Cerdanya
    Lleida, Spain
  • Centre Hospitalari Althaia
    Manresa, Spain
  • Hospital Comarcal Móra d'Ebre
    Móra d'Ebre, Spain
  • Hospital joan XXIII
    Tarragona, Spain
  • Hospital de Vic
    Vic, Spain
  • Hospital de Vilafranca
    Vilafranca Del Penedès, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03956485
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Fundació Ictus, Pla Director de la Malaltia vascular Cerebral, Departament de Salut
Responsible party
Sponsor
First posted
May 20, 2019
Start date
Sep 2019 (estimated)
Primary completion
Sep 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
May 20, 2019

Study contacts

Joan Martí-Fàbregas, MD,PhD
Contact
jmarti@santpau.cat
+34935565986

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion